This educational content was derived from the American College of Physicians (ACP) Internal Medicine Meeting 2017 in San Diego, California. This activity will focus on optimized treatment plans for patients with dyslipidemia in the era of PCSK9 inhibitor therapeutics. LDL-C has been identified as an important therapeutic target to prevent the progression of atherosclerotic disease, however only 1 out of every 3 adults with high LDL-C has the condition under control. Expert faculty on this panel will discuss the science of PCSK9 inhibitors and aid physicians in the best practices to get their patients at LDL-C target.
Look no further for the most cutting edge cardiology CME courses. We offer cardiology continuing medical education courses in dyslipidemia, acute coronary syndrome (acs), and Morquio A Syndrome, among others.
ACC 2017: A Therapeutic Update to Reduce Risk and Optimize Outcomes for Patients with Reduced or Preserved Ejection Fraction Heart FailureFormat: Webcast
This Official Elsevier Clinical Perspectives and Analysis will cover data presented at the American College of Cardiology 66th Annual Scientific Sessions and Expo held in Washington, DC. The four expert faculty will discuss the most up to date statistics and therapeutic advances for patients with preserved ejection fraction heart failure. The faculty will debate measures of prognosis and biomarkers to enhance treatment plans. Current clinical trial data will be examined in cross reference with new and emerging combination therapies to better serve patients. Upon completion of this activity physicians will gain a better understanding of treatment options to provide better outcomes for patients with ejection fraction heart failure.
This CME Program will highlight information presented at the European Society of Cardiology Congress 2016 held in Rome, Italy on August 27-31, 2016. Didactic presentation in combination with intermittent, interactive panel discussions will provide clinicians with a better understanding of the pathophysiology of hypercholesterolemia, including approaches for prevention and assessment of risk. Three expert faculty will decipher recent clinical trial data and communicate new treatment strategies, including those centered around PCSK9 usage, as well as best practices for patients with dyslipidemia. Discussion about the role and importance of the comprehensive healthcare team will ensue. Upon completing this program, clinicians responsible for the management of patients with dyslipidemia will be better equipped with the most up-to-date information to create tailored treatment plans and optimize patient outcomes.
ESC 2016: Applying Novel Therapeutics to Improve Outcomes in Patients with Pulmonary Arterial HypertensionFormat: Medical Meeting Reporter
This CME program will cover data on current and emerging therapeutic options for treating patients with pulmonary arterial hypertension (PAH) that was presented at the European Society of Cardiology 2016 Annual Congress held in Rome, Italy. The expert faculty will discuss recent clinical trial data on pulmonary arterial hypertension along with ways to integrate new information into daily practice. Clinicians will gain a better understanding of ways to improve outcomes for their patients with PAH by providing the most up-to-date care.
This CME program will focus on new and emerging therapeutic options in the management of patients with dyslipidemia that were discussed at the American Heart Association Annual Congress 2016 in New Orleans, Louisiana. The expert faculty will evaluate clinical trial data and the responsiveness to therapeutic agents. They will discuss the science behind new and emerging therapies, the efficacy and safety data supporting these therapies, and the role of new therapies alongside traditional dyslipidemia treatment options.
This discussion-based, CME program will feature imperative information for the treatment and management of patients with heart failure presented at the American Heart Association Scientific Sessions 2016 held in Orlando, Florida. Predictors of heart failure, patient assessment techniques and risk-benefit considerations for patients, both in the initiation of treatment and as treatment progresses, will be discussed. The three expert faculty will review newly released clinical trial data, particularly those pertaining to novel targeted therapeutics. Updates on major outcomes trials and the impending effect on clinical practice will be assessed. After participating in this activity, healthcare professionals will gain insight into optimal, personalized treatment and management strategies as well as methods of improving outcomes in patients with heart failure.
AHA 2016 Conference: Perspectives & Analysis: Heart Failure, Dyslipidemia and Non-Valvular Atrial FibrillationFormat: Medical Meeting Reporter
These discussion-based, CME programs feature imperative information for the treatment and management of patients with heart failure, dysplipidemia and non-valvular atrial fibrillation presented at the American Heart Association Scientific Sessions 2016 held in Orlando, Florida.
AHA 2016: An Update of Emerging Therapeutics to Prevent Stroke in Patients with Non-Valvular Atrial FibrillationFormat: Medical Meeting Reporter
This Official Elsevier Meeting Reporter will highlight recent science and clinical strategies for the management of patients with atrial fibrillation presented at the American Heart Association Scientific Sessions 2016 held in New Orleans, Louisiana. Expert faculty will discuss anticoagulant management, including prevention, diagnostic criteria and current treatment options. Updates on existing tactics for preventing stroke in the population of patients with atrial fibrillation will also be covered in the duration of this discussion-based activity. Faculty will relay optimal methods for educating newly diagnosed individuals and improving patient-physician communication lines as treatment progresses. Upon completion of this program, learners will find themselves better acquainted with the current science needed for accurate diagnosis as well as quality of life improvement in patients with atrial fibrillation.
This activity will focus on the most current clinical trial data for achieving LDL-C goal for all patients in the era of PCSK9 inhibitors as presented as an Unofficial Satellite Event at the American Heart Association Scientific Sessions 2016. The expert faculty utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide information that every cardiologists needs to know to improve healthcare outcomes in their patients with cardiovascular disease.